<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8FF79CF255C141DFB010FA3C9494F3D2" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 6584 IH: Diverse and Equitable Participation in Clinical Trials Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-02-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6584</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220203">February 3, 2022</action-date><action-desc><sponsor name-id="E000215">Ms. Eshoo</sponsor> (for herself, <cosponsor name-id="F000466">Mr. Fitzpatrick</cosponsor>, and <cosponsor name-id="K000385">Ms. Kelly of Illinois</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes.</official-title></form><legis-body id="HC877C9281F0541AF99A43308E9908D7D" style="OLC"><section id="H2970BB57B5EB4F26B713663EB6E42217" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Diverse and Equitable Participation in Clinical Trials Act</short-title></quote> or the <quote><short-title>DEPICT Act</short-title></quote>. <italic></italic></text></section><section id="H3A8CB5A8F65B4C72A3927FCC648D4BE4"><enum>2.</enum><header>Premarket reporting of diversity plans for clinical trials and studies</header><subsection id="HA46688E3C38E4401BBE31B86CF37E282"><enum>(a)</enum><header>Drugs</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs shall issue regulations revising part 312 of title 21, Code of Federal Regulations, to require sponsors of applications for an exemption for investigational use of a drug to include—</text><paragraph id="H6BA56A932C554C7BA22ADD20EFC44D87"><enum>(1)</enum><text display-inline="yes-display-inline">in any such application—</text><subparagraph id="H224C4CC39DF54C1B9B01475BDFE347FD"><enum>(A)</enum><text display-inline="yes-display-inline">the estimated prevalence in the United States of the disease or condition for which the drug is being developed or investigated, disaggregated by demographic subgroup, where such data is available, including age group, sex, race, and ethnicity;</text></subparagraph><subparagraph id="HEF61E8A6782E406C952F9EB23CBE7CC4"><enum>(B)</enum><text display-inline="yes-display-inline">the sponsor’s targets for enrollment in the clinical trial or trials involved, disaggregated by age group, sex, race, and ethnicity; </text></subparagraph><subparagraph id="H63D9E3794C86442AA3051508D932B4CA"><enum>(C)</enum><text display-inline="yes-display-inline">the rationale for the sponsor’s enrollment targets referred to in subparagraph (B), which may include—</text><clause id="HE4C87CED9B9C453D8B28046AA81EEBF1"><enum>(i)</enum><text>the estimated prevalence referred to in subparagraph (A);</text></clause><clause id="H85ED997BA6D74C01A1A34CD1D4666791"><enum>(ii)</enum><text>what is known about the disease or condition for which the drug is being developed or investigated;</text></clause><clause id="H32646E6C025D43928A88E3337F3BB232"><enum>(iii)</enum><text>any relevant pharmacokinetic or pharmacogenomic data;</text></clause><clause id="H0E14DE1557D74E3B8B669AE46F2D2A17"><enum>(iv)</enum><text>what is known about the patient population, including co-morbidities and potential barriers to enrolling diverse participants, such as patient population size and geographic location; and </text></clause><clause id="HA88FD226A96140978FE76302EA10C3CA"><enum>(v)</enum><text>any other data or information the sponsors deems relevant to selecting appropriate enrollment targets, disaggregated by demographic subgroup; and</text></clause></subparagraph><subparagraph id="HC2C905666E18401EAC71125221A3C5A1"><enum>(D)</enum><text display-inline="yes-display-inline">a diversity action plan for how the sponsor will meet such targets, including demographic-specific outreach and enrollment strategies, study-site selection, clinical trial inclusion and exclusion practices, and any diversity training for trial personnel; and</text></subparagraph></paragraph><paragraph id="HB7633AB5E4FD422B916CDC74C44EBCC9"><enum>(2)</enum><text display-inline="yes-display-inline">in an annual report described in section 312.33 of title 21, Code of Federal Regulations—</text><subparagraph id="HB594850EB28E42F0B51D2A1607258C3C"><enum>(A)</enum><text>the sponsor’s progress in meeting the targets referred to in paragraph (1)(B); and</text></subparagraph><subparagraph id="HF5A4374ECF1640EB9E7EA6E9427886E5"><enum>(B)</enum><text display-inline="yes-display-inline">if the sponsor does not expect to meet those targets referred to in paragraph (1)(B)—</text><clause id="HDC98641049B340E7A7FF8F77105D0A67"><enum>(i)</enum><text>any updates needed to be made to the diversity action plan referred to in paragraph (1)(D) to meet such targets; or</text></clause><clause id="H0F7A65632DCD4BDC938C80A623596C04"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor’s justification for why the sponsor does not expect to meet such targets, including—</text><subclause id="H3B5F7B727E24404494576BBDF47856AB"><enum>(I)</enum><text>any factors outside of the sponsor’s control, including a lack of retention of participants;</text></subclause><subclause id="H8407D1CFEF8D459CBA5AD1B50B4F9DBE"><enum>(II)</enum><text>any differences in the enrollment targets, disaggregated by demographic subgroup, and actual enrollment that the sponsor determines are insignificant in nature;</text></subclause><subclause id="H9EE1E3DAF05A410C9711FF934BF48F73"><enum>(III)</enum><text>potential for selection bias; and</text></subclause><subclause id="H58E799CF6D0145C59E022DBC13A01C6A"><enum>(IV)</enum><text>information not available to the sponsor at the time such targets were chosen, but that impacted enrollment of diverse participants.</text></subclause></clause></subparagraph></paragraph></subsection><subsection id="HEDEF2D9181B64A6AB650424F189CC8E4"><enum>(b)</enum><header>Devices</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs shall issue regulations revising part 812 of title 21, Code of Federal Regulations, to require sponsors of applications for an exemption for investigational use of a device to include—</text><paragraph id="H33D3FF99A9BA44ABB784F03F6D6D6D87"><enum>(1)</enum><text>in any such application—</text><subparagraph id="H5F03275110F7404BA97E7522E1B30742"><enum>(A)</enum><text display-inline="yes-display-inline">a description of the patient population in the United States expected to use the device, disaggregated by demographic subgroup, where such data is available, including age group, sex, race, and ethnicity;</text></subparagraph><subparagraph id="H81B20C1F28C34DAB92A124863C56C62E"><enum>(B)</enum><text>the sponsor’s targets for enrollment in the clinical trial or trials involved, disaggregated by age group, sex, race, and ethnicity;</text></subparagraph><subparagraph id="HA7C6E7C90A4A4772B22EAA1F17AD5F06"><enum>(C)</enum><text display-inline="yes-display-inline">the rationale for the sponsor’s enrollment targets referred to in subparagraph (B), which may include—</text><clause id="HA7EB537CD1C749DDB6DEDB84CAE8119A"><enum>(i)</enum><text>the estimated prevalence referred to in subparagraph (A);</text></clause><clause id="H7058E3DB8ABA40CC81BCB8861BF15483"><enum>(ii)</enum><text>what is known about the disease or condition for which the drug is being developed or investigated;</text></clause><clause id="H0CBE816B6D4A4623B7C8734A401ABFB4"><enum>(iii)</enum><text>any relevant pharmacokinetic or pharmacogenomic data;</text></clause><clause id="H418A3DF0D81649819BF660C5F2595DA7"><enum>(iv)</enum><text>what is known about the patient population, including co-morbidities and potential barriers to enrolling diverse participants, such as patient population size and geographic location; and </text></clause><clause id="H5D33FFD126FF4365994396ACA475CA27"><enum>(v)</enum><text>any other data or information the sponsors deems relevant to selecting appropriate enrollment targets, disaggregated by demographic subgroup; and</text></clause></subparagraph><subparagraph id="H8B33A05F21454E528C379C4E4488EFAA"><enum>(D)</enum><text display-inline="yes-display-inline">a diversity action plan for how the sponsor will meet such targets, including demographic-specific outreach and enrollment strategies, study-site selection, clinical trial inclusion and exclusion practices, and any diversity training for trial personnel; and</text></subparagraph></paragraph><paragraph id="HF9E3862049E74A6487A63DF0E65EFAA2"><enum>(2)</enum><text display-inline="yes-display-inline">in an annual report described in section 812.150 of title 21, Code of Federal Regulations—</text><subparagraph id="HABDD1169C21A4472A49499CBF876EF68"><enum>(A)</enum><text display-inline="yes-display-inline">the sponsor’s progress in meeting those targets referred to in paragraph (1)(B); and</text></subparagraph><subparagraph id="H68CA568C2FBF4DC4B1076C39F53DA0A9"><enum>(B)</enum><text display-inline="yes-display-inline">if the sponsor does not expect to meet those targets referred to in paragraph (1)(B)—</text><clause id="H6CD89913ED32454CAC85351DDACDA098"><enum>(i)</enum><text>any updates needed to be made to the diversity action plan referred to in paragraph (1)(D) to meet such targets; or</text></clause><clause id="HA64B30875BE44E6B8BF122A88D14D0F1"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor’s justification for why the sponsor does not expect to meet such targets, including—</text><subclause id="H9FF355F86B1D465392D9FDF6588E4499"><enum>(I)</enum><text>any factors outside of the sponsor’s control, including a lack of retention of participants;</text></subclause><subclause id="H4A9108B6D12B4FEABF2F91F42FFEDE86"><enum>(II)</enum><text>any differences in the enrollment targets, disaggregated by demographic subgroup, and actual enrollment that the sponsor determines are insignificant in nature;</text></subclause><subclause id="H36EC8221E67E406B95B7F9426F522E92"><enum>(III)</enum><text>potential for selection bias; and</text></subclause><subclause id="HFD298CF92B8B41C4A20AD1BDCA6DF8E7"><enum>(IV)</enum><text>information not available to the sponsor at the time such targets were chosen, but that impacted enrollment of diverse participants.</text></subclause></clause></subparagraph></paragraph></subsection><subsection id="H46F1CF98C53142AC950E81683E59CA84"><enum>(c)</enum><header>Additional clinical trial data</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs shall issue regulations revising sections 807.92 and 814.20 of title 21, Code of Federal Regulations, to require that applications for devices approved under section 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360e">21 U.S.C. 360e</external-xref>) and devices cleared under section 510(k) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(k)</external-xref>) whose submission includes clinical data—</text><paragraph id="H1579F6DBD0FE484EB06071DD502F211A"><enum>(1)</enum><text>a description of the patient population in the United States expected to use the device, disaggregated by demographic subgroup, where such data is available, including age group, sex, race, and ethnicity; and</text></paragraph><paragraph id="HB4D10057FF8F401D93953BD396F57465"><enum>(2)</enum><text>in summarizing the clinical investigations involving human subjects in such applications, a description of study subjects by demographic subgroup, including age group, sex, race, and ethnicity.</text></paragraph></subsection><subsection id="H402B807B82794E9284EFC6A5219D6D0B"><enum>(d)</enum><header>Deadline for promulgation</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs shall issue—</text><paragraph id="H496D54FFF60F4E6FBAB64A703F08646E"><enum>(1)</enum><text>any proposed rules required under this section not later than 2 years after the date of the enactment of this Act; and</text></paragraph><paragraph id="HD40E0443A063475D9D62D4FEBA85121E"><enum>(2)</enum><text display-inline="yes-display-inline">any final rules required under this section not later than 3 years after the date of the enactment of this Act.</text></paragraph></subsection></section><section id="HACF32C0F1F744027BE707C6EEF03D685"><enum>3.</enum><header>FDA authority to mandate postapproval studies or postmarket surveillance due to insufficient demographic subgroup data</header><subsection id="H5BAF5473D9BF4E13A5671EC9E2CECA1E"><enum>(a)</enum><header>Drugs</header><paragraph id="HF467139ABB9744209745D64E6F5FD9B6"><enum>(1)</enum><header>In general</header><text>Section 505(o)(3)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(3)(B)</external-xref>) is amended by adding at the end the following: </text><quoted-block style="OLC" id="H29969B2DBCB640F4A74A3ADBE441DEDA" display-inline="no-display-inline"><clause id="H519BFA9329E544B69BA783E545D5A526"><enum>(iv)</enum><text display-inline="yes-display-inline">To provide safety and effectiveness data for the drug involved for a demographic subgroup or subgroups, if—</text><subclause id="HD9CB315B328749C59D312DD22DC42BC7"><enum>(I)</enum><text>the clinical trials conducted in support of the approval of the drug did not meet the applicable targets of enrollment, as described in section 2 of the DEPICT Act; and</text></subclause><subclause id="H1C95087EBD0446F68A6FB0E5A26579F8"><enum>(II)</enum><text>in the judgment of the Secretary, additional data could inform drug labeling.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H74DBFC475D9147AE98503F65DF2BE720"><enum>(2)</enum><header>Waiver</header><text>Section 505(o)(3)(D) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(3)(D)</external-xref>) is amended by adding at the end the following: </text><quoted-block style="OLC" id="H1863236636D64DABB7E5DE5CAFBFCB45" display-inline="no-display-inline"><clause id="H7ED89FB744AF49D0933B02470B71A769"><enum>(iii)</enum><header>Clinical trial diversity enrollment</header><text display-inline="yes-display-inline">The Secretary may not require postapproval studies or postapproval clinical trials for the purpose specified under subparagraph (B)(iv) if the sponsor provides to the Secretary a sufficient justification for not meeting the enrollment targets referred to in such subparagraph, which may include—</text><subclause id="HE08E610659E84BCA8585F5C6C31AB613"><enum>(I)</enum><text display-inline="yes-display-inline">factors outside of the sponsor’s control, such as a lack of retention of participants;</text></subclause><subclause id="H373E6B8BF331444CB4516F03754BE76D"><enum>(II)</enum><text>differences in the enrollment targets, disaggregated by demographic subgroup, and actual enrollment that are determined by the Secretary to be insignificant in nature;</text></subclause><subclause id="HFC9374747C584FBC97B692853C748BDF"><enum>(III)</enum><text>information not available to the sponsor at the time such enrollment targets were chosen, but that impacted enrollment of diverse participants;</text></subclause><subclause id="H931B78CD6B60435592503304A3FD953F"><enum>(IV)</enum><text>potential for selection bias; and</text></subclause><subclause id="HC3732B1064384307BE87E76F41C4C1FA"><enum>(V)</enum><text>any other reason that the Secretary determines is sufficient justification. </text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H55A63A80DB8745289BE3B0B3FBE7CCBE"><enum>(3)</enum><header>Use of real world evidence</header><text display-inline="yes-display-inline">Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)(3)</external-xref>) is amended by adding at the end the following: </text><quoted-block style="OLC" id="HC1C146DDD00E416C9DB380C3F099012E" display-inline="no-display-inline"><subparagraph id="H61E4666B3A454DCEA65F6C0C824603F4"><enum>(G)</enum><header>Use of real world evidence</header><text display-inline="yes-display-inline">Real world evidence (as defined in section 505F(b)) may be used to support or satisfy the requirements under this paragraph.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H381754E3D3CF48CC981163CB8B018230" commented="no"><enum>(b)</enum><header>Devices</header><text display-inline="yes-display-inline">Section 522(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360l">21 U.S.C. 360l(a)(1)(A)</external-xref>) is amended—</text><paragraph id="H833823737424479495C3300437A4E7EF" commented="no"><enum>(1)</enum><text>in subparagraph (A)—</text><subparagraph id="HEC41F1B86E7444B89BD7636F9F0BE2C0"><enum>(A)</enum><text>in clause (ii), by striking <quote>or</quote> at the end; </text></subparagraph><subparagraph id="H58CD55A3883847A193D1D3A81512F5B8" commented="no"><enum>(B)</enum><text>in clause (iii)(II), by striking <quote>facility.</quote> and inserting <quote>facility; or</quote>; and</text></subparagraph><subparagraph id="H4886C75F7D0B42CBBB12E099F96665FA" commented="no"><enum>(C)</enum><text>by adding at the end the following: </text><quoted-block style="OLC" id="HDF569A3609D64CCF8361AA503E4DAC2F" display-inline="no-display-inline"><clause id="H9E22CB2DFB334027801735D8647B7CDB" commented="no"><enum>(iv)</enum><text display-inline="yes-display-inline">with respect to which—</text><subclause id="H0C179FDA4FF142D09DBE1CCCE56FAEE8" commented="no"><enum>(I)</enum><text display-inline="yes-display-inline">clinical studies submitted to support that approval or clearance did not meet the applicable targets of enrollment, as described in section 2 of the DEPICT Act; and</text></subclause><subclause id="H83B9FE012FBE443FA4EF7C60D18D074F" commented="no"><enum>(II)</enum><text>with respect to which a justification described in subparagraph (D) is not provided.</text></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H6CB6D233E3EC418CB1AE7DA749A55232"><enum>(2)</enum><text>by adding at the end the following: </text><quoted-block style="OLC" id="HA86EAF6B71924AB9A94D05BC651363A4" display-inline="no-display-inline"><subparagraph id="H9964388E2C304E58BD6380B71C69478C"><enum>(C)</enum><header>Use of real world evidence</header><text display-inline="yes-display-inline">Real world evidence (as defined in section 505F(b)) may be used to support or satisfy the requirements under this paragraph.</text></subparagraph><subparagraph id="HD27E80A38A4A42A9967765887E1DEE5E"><enum>(D)</enum><header>Clinical trial diversity enrollment</header><text display-inline="yes-display-inline">The Secretary may not require a manufacturer to conduct postmarket surveillance under subparagraph (A) with respect to a device for the purpose specified in clause (iv) of such subparagraph if the manufacturer provides to the Secretary a sufficient justification for not meeting the enrollment targets referred to in such subparagraph, which may include—</text><clause id="H898326C02CD143CBB78B15D25C4ECA01"><enum>(i)</enum><text display-inline="yes-display-inline">factors outside of the manufacturer’s control, such as a lack of retention of participants;</text></clause><clause id="HE19C6A151A154294A3FDADB11B900B7A"><enum>(ii)</enum><text>differences in the enrollment targets, disaggregated by demographic subgroup, and actual enrollment that are determined by the Secretary to be insignificant in nature;</text></clause><clause id="H38CA72AA6C704303A551E27F9AD2C940"><enum>(iii)</enum><text>information not available to the manufacturer at the time such enrollment targets were chosen, but that impacted enrollment of diverse participants;</text></clause><clause id="H6586B63750CD4BB9AA7DB657389864EE"><enum>(iv)</enum><text>potential for selection bias; and</text></clause><clause id="H42912EA99A4C4804A051EAE1C2858906"><enum>(v)</enum><text>any other reason that the Secretary determines is sufficient justification. </text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H0BD80D6E1B8445DD9511B837BB730357"><enum>(c)</enum><header>Reports for certain devices</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs shall issue regulations revising section 814.84 of title 21, Code of Federal Regulations, to require holders of an application approved under section 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360e">21 U.S.C. 360e</external-xref>) to include in the reports submitted under such section 814.84, to the extent possible, any data not previously submitted under such section 814.84 that may inform the safety and effectiveness of the device involved in underrepresented demographic subgroups.</text></subsection><subsection id="HBC21C553C110454CB8AA314DA98DB758"><enum>(d)</enum><header>Registry and results data bank inclusion</header><text display-inline="yes-display-inline">Section 402(j)(1)(A) of the Public Health Service Act (282(j)(1)(A)) is amended—</text><paragraph id="H22B80710265647F5BD7717AB231B9226"><enum>(1)</enum><text display-inline="yes-display-inline">in clause (ii)—</text><subparagraph id="H2E47C4B83DA64727AD4BD951C66AF4A7"><enum>(A)</enum><text>in subclause (I), by striking <quote>and</quote> at the end;</text></subparagraph><subparagraph id="H74C4CD851C4F42FDB4FAC30EB91ACE5E"><enum>(B)</enum><text>in subclause (II), by striking the period at the end and inserting <quote>; and</quote>; and</text></subparagraph><subparagraph id="H4F9EF97246AF42B7AF90AC647866624D"><enum>(C)</enum><text>by adding at the end the following: </text><quoted-block style="OLC" id="H3E9588B5FF5A4D0EBD6D172D24E1F9EA" display-inline="no-display-inline"><subclause id="H24DCE5E14F1946F9AED37898DE099E02"><enum>(III)</enum><text display-inline="yes-display-inline">postmarket surveillance for any device as required under clause (iv) of section 522(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act.</text></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H6DF53A2F273A440BA30A12DED6891973"><enum>(2)</enum><text>in clause (iii)(I), by striking the period at the end and inserting the following: <quote>, including any postapproval study or postapproval clinical trial for a drug as required under section 505(o)(3)(B)(iv) of the Federal Food, Drug, and Cosmetic Act.</quote>.</text></paragraph></subsection><subsection id="H2AA8A8C36117412BB309893506EC27D3"><enum>(e)</enum><header>Public meeting</header><paragraph id="H892B772119944ABBB32694058A61F8EA"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 270 days after the date of enactment of this Act, the Secretary, acting through the Commissioner of Food and Drugs, and in consultation with drug sponsors, medical device manufacturers, patients, and other stakeholders, shall convene a public meeting to consider the ways by which—</text><subparagraph id="H8DADACF9B5374481B030F85007202E09"><enum>(A)</enum><text display-inline="yes-display-inline">drug sponsors and medical device manufacturers may disseminate information to the public on clinical trial enrollment demographic data in a timely and accessible manner;</text></subparagraph><subparagraph id="H11BAAF71A4D94A64AB519BFC7CEC29C8"><enum>(B)</enum><text>drug and device sponsors, in consultation with the Commissioner of Food and Drugs, may publicly disseminate information on subgroup analyses conducted by the sponsors in cases where—</text><clause id="HD385D96F0FA8487D9DBCF706E035ED49"><enum>(i)</enum><text>such data is not sufficient for the purpose of updating drug and device labels; or</text></clause><clause id="H81616ACA64304A9EB8AD98B101D77DCD"><enum>(ii)</enum><text>such analyses do not show significant differences between demographic subgroups; and</text></clause></subparagraph><subparagraph id="HCD1332EF64C846E795A669C02D8677C9"><enum>(C)</enum><text display-inline="yes-display-inline">drug and device sponsors, in consultation with the Commissioner of Food and Drugs, may collect and publicly disseminate real world evidence that may provide information on the safety and effectiveness of drugs or devices for a demographic subgroup or subgroups.</text></subparagraph></paragraph><paragraph id="HC1025660F4A547EAA55211C411EE9095"><enum>(2)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 180 days after the date on which the public meeting is convened under paragraph (1), the Secretary shall make available on the website of the Food and Drug Administration a report on the topics discussed at such meeting. The report shall include a summary of, and response to, recommendations raised in such meeting.</text></paragraph></subsection></section><section id="HE27CBD3B8BD64BAFB0381021A321374D"><enum>4.</enum><header>Annual report on progress to increase diversity in clinical trials and studies</header><subsection id="HCE8C0F411BA144DA89F04BE5F1E61464"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Beginning not later than 2 years after the date of the enactment of this Act, and each year thereafter, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit to Congress, and publish on the public website of the Food and Drug Administration, a report that addresses progress on increasing diversity in clinical trial and study enrollment. </text></subsection><subsection id="HF85396D6111542029E084AE323AF792C"><enum>(b)</enum><header>Contents of report</header><text>The report submitted under subsection (a) shall include, with respect to applications for drugs or devices approved or cleared under section 505, 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), or 360e) or licensed under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) during the calendar year that immediately precedes the year in which the report is submitted—</text><paragraph id="H11241A61F0AF4CA8B1D87CAF5D84978C"><enum>(1)</enum><text display-inline="yes-display-inline">an analysis of the extent to which clinical trials conducted with respect to such applications have met the demographic subgroup enrollment targets for clinical trials and studies required by the regulations amended pursuant to section 2 and the amendments made by section 3;</text></paragraph><paragraph id="H507936FDF8064B6D8E97DAB3E668467D"><enum>(2)</enum><text display-inline="yes-display-inline">the frequency with which enrollment targets by demographic subgroup set for a clinical trial conducted under an exemption for investigational use of a drug under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) or an exemption for investigational use of a device under section 520(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">21 U.S.C. 360j(g)</external-xref>) do not adequately reflect the incidence in the United States population of the disease or condition being studied in the clinical trial and a summary of the rationales provided for enrollment targets by demographic subgroup in such cases;</text></paragraph><paragraph id="H2D967427385643C88F1C55AD8104CE83"><enum>(3)</enum><text display-inline="yes-display-inline">a summary of the justifications sponsors provided in the cases where sponsors did not meet the enrollment targets specified pursuant to section 2, disaggregated by demographic subgroup; and</text></paragraph><paragraph id="H99DF1600F4E44FA9A9205BEBD42D90FB"><enum>(4)</enum><text>the Secretary’s recommendations, as appropriate, for strategies presented in such diversity plans to attain enrollment targets that should be adopted by sponsors as best practices.</text></paragraph></subsection><subsection id="H6535E419148F4772B9BD97F8AA94FC21"><enum>(c)</enum><header>Postmarket studies</header><text display-inline="yes-display-inline">Beginning 3 years after the first instance in which the Secretary requires the sponsor of an application for a drug or device approved or cleared under section 505, 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), or 360e) or licensed under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) to conduct postmarket studies or postmarket surveillance under clause (iv) of section 505(o)(3)(B) and clause (iv) of section 522(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act (as added by subsections (a) and (b) of section 3), and each year thereafter, the report submitted under subsection (a) shall also include—</text><paragraph id="H9DA21D29BB8246AFB00FDB0A940C3DEA"><enum>(1)</enum><text display-inline="yes-display-inline">the number of such applications that were required to initiate postmarket studies or surveillance in the previous calendar year under clause (iv) of section 505(o)(3)(B) and clause (iv) of section 522(a)(1)(A) of the Federal Food, Drug, and Cosmetic Act (as added by subsections (a) and (b) of section 3), the numbers of such applications that have, <italic></italic>as of the end of the calendar year immediately preceding the year in which the report is submitted, in-progress postmarket requirements, and the number of such applications that have completed postmarket requirements for each year, beginning on the date of the enactment of this Act;</text></paragraph><paragraph id="H128D9C69417942D1BDA4BFB1F00E7360"><enum>(2)</enum><text>an analysis of the average amount of time for completion of such postmarket requirements, disaggregated by type of application and type of postmarket requirement;</text></paragraph><paragraph id="HC5E3DBB41749423F964DE0489DF8BC5B"><enum>(3)</enum><text>an analysis of how the imposition of such postmarket requirements has impacted the availability of demographic subgroup-specific safety and efficacy data for drugs, biologics, and devices; and</text></paragraph><paragraph id="H65545F507D5142B7A6B30D76C425D069"><enum>(4)</enum><text display-inline="yes-display-inline">the Secretary’s recommendations, as appropriate, for additional guidance or postmarket requirements to facilitate the collection and reporting of representative demographic subgroup data in support of applications for the approval or clearance of, or updates to the labeling of, drugs and devices under section 505, 510(k), or 515 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>, 360(k), or 360e) or licensure of biological products under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text></paragraph></subsection><subsection id="HD21D8AE772624AD3A778B9E34CEDB0C0"><enum>(d)</enum><header>Confidentiality</header><text display-inline="yes-display-inline">Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.</text></subsection></section><section id="HB8D9EB9DC59148DBA0B5FBE249720FE0"><enum>5.</enum><header>Public meeting on clinical trial flexibilities initiated in response to COVID–19 pandemic</header><subsection id="HD89F655F8AB548DEB0C20513E46440EE"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 180 days after the date on which the COVID–19 emergency period ends, the Secretary of Health and Human Services shall convene a public meeting to discuss the regulatory flexibilities adopted by the Food and Drug Administration during the COVID–19 emergency period to mitigate disruption of clinical studies and clinical trials, including flexibilities detailed in the March 2020 guidance entitled <quote>Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency, Guidance for Industry, Investigators, and Institutional Review Boards</quote>, and any subsequent updates to such guidance. The Secretary shall invite to such meeting representatives from the pharmaceutical and medical device industries who sponsored clinical trials and clinical studies during the COVID–19 emergency period and organizations representing patients.</text></subsection><subsection id="HB3FEF6B06454453CBE9C8FCD9CF3A18E"><enum>(b)</enum><header>Topics</header><text display-inline="yes-display-inline">Not later than 90 days after the date on which the public meeting under subsection (a) is convened, the Secretary shall make available on the public website of the Food and Drug Administration a report on the topics discussed at such meeting. Such topics shall include discussion of— </text><paragraph id="H9D82396FD4E340738CBC29A9246F2A11"><enum>(1)</enum><text>the actions drug sponsors took to utilize such regulatory flexibilities and the frequency at which such flexibilities were employed;</text></paragraph><paragraph id="HBA8F836BFB934AB0B1639D82D3539128"><enum>(2)</enum><text>the characteristics of the sponsors, trials, and patient populations impacted by such regulatory flexibilities;</text></paragraph><paragraph id="HEAD09EE03BC74450B58A315F8A20B3BD"><enum>(3)</enum><text>a consideration of how regulatory flexibilities to mitigate disruption of clinical trials during the COVID–19 emergency period, including decentralized clinical trials, may have affected access to clinical studies and trials for certain patient populations, especially unrepresented racial and ethnic minorities; and</text></paragraph><paragraph id="H05278AEF2BE84B20A0E973C90A5D2099"><enum>(4)</enum><text>recommendations for incorporating certain clinical trial disruption mitigation flexibilities into current or additional guidance to improve clinical trial access and enrollment of diverse patient populations.</text></paragraph></subsection><subsection id="HE3324964A3974A649850EBA9903F6864"><enum>(c)</enum><header>COVID–19 emergency period defined</header><text>In this section, the term <quote>COVID–19 emergency period</quote> has the meaning given the term <quote>emergency period</quote> in section 1135(g)(1)(B) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320b-5">42 U.S.C. 1320b–5(g)(1)(B)</external-xref>).</text></subsection></section><section id="HE32B0376A07346268747925C2493FE3A" commented="no"><enum>6.</enum><header>Community engagement and outreach to improve inclusion of underrepresented minorities in clinical trials and research</header><subsection id="HBDE83BCDE9EF4B009F588C15C023F80E" commented="no"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, shall conduct, coordinate, and support activities for purposes of community engagement with, and outreach to, underserved communities to facilitate inclusion of underrepresented minorities in clinical research and clinical trials.</text></subsection><subsection id="H9C81027EF02C451FBEDB01D7E7448EDF" commented="no"><enum>(b)</enum><header>Activities</header><text>Activities conducted, coordinated, or supported under this section may be for any of the following purposes:</text><paragraph id="HBF8506CB51D04F309CE1DE71FF1798A3" commented="no"><enum>(1)</enum><text display-inline="yes-display-inline">Developing and disseminating best practices for community engagement and outreach and for inclusive participation in clinical research and trials.</text></paragraph><paragraph id="H9D4E991A3F28472DADDC73D7BD379611" commented="no"><enum>(2)</enum><text>Creating and providing tools and educational resources—</text><subparagraph id="H229A975859B84169BE587B4417D55E77" commented="no"><enum>(A)</enum><text>to facilitate adoption of such best practices by researchers and clinical trial sponsors; and</text></subparagraph><subparagraph id="HDFF3F52E52734D2FAC49DB00C90F8C53" commented="no"><enum>(B)</enum><text>to encourage awareness of, and participation in, clinical trials and research among underrepresented minorities.</text></subparagraph></paragraph><paragraph id="HCF3D752F38054F88BDFB380E44956D07" commented="no"><enum>(3)</enum><text>Engaging community stakeholders in underrepresented racial and ethnic minority communities and fostering partnerships with community-based organizations serving underrepresented racial and ethnical minority populations to encourage participation in clinical trials and research.</text></paragraph><paragraph id="H539AB3C56AF840AAABBD02C2E31E62A0"><enum>(4)</enum><text>Conducting and supporting community engagement research.</text></paragraph></subsection><subsection id="HAF70FD39E4434FF9A05A665C76DD96ED"><enum>(c)</enum><header>Supplement, not supplant</header><text display-inline="yes-display-inline">Grants under this subsection shall be used to supplement and not supplant existing initiatives and programs at the National Institutes of Health to improve diversity in clinical trials and research. </text></subsection></section><section id="HFACFADCC1DA440BB9FFC13950E33F13B"><enum>7.</enum><header>Grants to increase the capacity of community health centers to participate in clinical trials and research</header><subsection id="H4B41573798894A0C85D8EA433F4462C1"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration and in consultation with the Director of the National Institutes of Health, shall award grants to, and enter into cooperative agreements with, qualified entities to increase capacity at such qualified entities to participate in clinical trials and research by—</text><paragraph id="HC7E0F5610EE5476B8EDC030466CF2ABA"><enum>(1)</enum><text display-inline="yes-display-inline">enhancing and expanding infrastructure at community health centers to support participation in clinical trials and research, including information technology improvements and the hiring and training of healthcare personnel, such as patient navigators and culturally trained site personnel to conduct, or recruit for, clinical trials;</text></paragraph><paragraph id="H134893192DA24B7297ACAE80265B6ADD"><enum>(2)</enum><text display-inline="yes-display-inline">reimbursing administrative costs and patient care costs incurred by qualified entities in the course of clinical research and trials that are not otherwise reimbursable by existing payers; and</text></paragraph><paragraph id="H4C2C41E703DA40E5BB26E037F7E75B6F"><enum>(3)</enum><text>implementing community education and outreach strategies.</text></paragraph></subsection><subsection id="H68763EEA61B446EF893695D1A8D72196"><enum>(b)</enum><header>Qualified entities defined</header><text>In this section, the term <quote>qualified entity</quote> means—</text><paragraph id="H41A4AE8348B2456E8738FE6ED1FB19D9"><enum>(1)</enum><text>rural health clinics, as defined in section 1861(aa)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(aa)(2)</external-xref>);</text></paragraph><paragraph id="H6BE9C384549F4E0EB8502343EAD96E6B"><enum>(2)</enum><text display-inline="yes-display-inline">federally-qualified health centers described in section 1861(aa)(4)(B) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(aa)(4)(B)</external-xref>);</text></paragraph><paragraph id="HB3431F19A62F41409ABE9DFE3F4968A0"><enum>(3)</enum><text>facilities operated by the Indian Health Service, an Indian Tribe, Tribal Organization, or an Urban Indian organization, as those terms are defined in section 4 of the Indian Health Care Improvement Act (<external-xref legal-doc="usc" parsable-cite="usc/25/1603">25 U.S.C. 1603</external-xref>); and</text></paragraph><paragraph id="H87A7E2D349974927B193D8F269F902A2"><enum>(4)</enum><text>entities eligible to receive funds under section 330 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/254b">42 U.S.C. 254b</external-xref>).</text></paragraph></subsection></section><section id="H9082276B5B4F475EA9A284BDF9E5D902"><enum>8.</enum><header>Authorization of appropriations</header><text display-inline="no-display-inline">There is authorized to be appropriated to carry out this Act, $100,000,000 for the period of fiscal years 2022 through 2025. </text></section></legis-body></bill> 

